NCT05909527 2026-03-17
A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
Guangzhou Bio-gene Technology Co., Ltd
Phase 1/2 Withdrawn
Clinical Trials
57 trialsNCT04607772 2025-10-03
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Therapeutics Inc
Phase 1/2 Withdrawn
NCT06005649 2025-08-08
Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Juventas Cell Therapy Ltd.
Phase 1/2 Withdrawn
NCT06009107 2025-08-08
B-ALL
Juventas Cell Therapy Ltd.
Phase 1/2 Withdrawn
NCT05538988 2025-06-27
BIOSELECT
AHS Cancer Control Alberta
Phase 1/2 Withdrawn
NCT04148742 2025-02-25
Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
Dizal Pharmaceuticals
Phase 1/2 Withdrawn
NCT03169790 2025-02-24
QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT03417765 2024-10-24
Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas
VectivBio AG
Phase 1/2 Withdrawn
NCT05936229 2024-07-12
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Fred Hutchinson Cancer Center
Phase 1/2 Withdrawn
NCT05740449 2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Withdrawn
NCT05895201 2024-04-29
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Indiana University
Phase 1/2 Withdrawn
NCT03098355 2024-03-18
Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
Zhujiang Hospital
Phase 1/2 Withdrawn
NCT05613348 2024-03-18
CAR19T2
Zhujiang Hospital
Phase 1/2 Withdrawn
NCT05201183 2023-12-11
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Indiana University
Phase 1/2 Withdrawn
NCT05320380 2023-09-01
A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Children's Oncology Group
Phase 1/2 Withdrawn
NCT04029038 2023-08-21
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00816413 2023-08-14
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
University of Nebraska
Phase 1/2 Withdrawn
NCT05604417 2023-07-07
Zandelisib + Tazemetostat in R/R Follicular Lymphoma
Massachusetts General Hospital
Phase 1/2 Withdrawn
NCT05152459 2023-05-31
Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT01138579 2022-12-07
STP-LYM-01
Technical University of Munich
Phase 1/2 Withdrawn
NCT05570188 2022-11-30
Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies
Kunming Hope of Health Hospital
Phase 1/2 Withdrawn
NCT03880279 2022-02-23
TACTIC-19
Triumvira Immunologics, Inc.
Phase 1/2 Withdrawn
NCT03851081 2022-01-28
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
Roswell Park Cancer Institute
Phase 1/2 Withdrawn
NCT04882163 2021-10-05
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Celgene
Phase 1/2 Withdrawn
NCT03873025 2021-08-17
PLACARD
University College, London
Phase 1/2 Withdrawn
NCT03586024 2021-05-07
Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas
Abramson Cancer Center at Penn Medicine
Phase 1/2 Withdrawn
NCT03553914 2020-10-19
PLM60 for Peripheral T Cell Lymphoma (PTCL)
Conjupro Biotherapeutics, Inc.
Phase 1/2 Withdrawn
NCT01460602 2020-09-01
Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma
Louisiana State University Health Sciences Center Shreveport
Phase 1/2 Withdrawn
NCT02547948 2020-07-16
CD19-targeting CAR T Cells for B Cell Lymphoma
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Withdrawn
NCT04260009 2020-03-05
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
Takeda
Phase 1/2 Withdrawn
NCT01415765 2019-12-17
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT02729961 2019-10-10
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
University of Washington
Phase 1/2 Withdrawn
NCT02053545 2019-08-30
Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1/2 Withdrawn
NCT00829647 2019-04-11
A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
Scripps Health
Phase 1/2 Withdrawn
NCT02228512 2018-08-31
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT02545361 2018-08-16
Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients
Kahr Medical
Phase 1/2 Withdrawn
NCT02722551 2018-01-09
RELIEF
Edwards Lifesciences
Phase 1/2 Withdrawn
NCT02229981 2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2 Withdrawn
NCT01163201 2017-12-02
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Masonic Cancer Center, University of Minnesota
Phase 1/2 Withdrawn
NCT02677948 2017-09-06
Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
University of Michigan Rogel Cancer Center
Phase 1/2 Withdrawn
NCT02408042 2017-06-27
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
Western Regional Medical Center
Phase 1/2 Withdrawn
NCT00637117 2017-06-12
Intratumoral Dendritic Cell Vaccination Combined With Local Radiotherapy in Patients With Recurrent Lymphoma.
Baylor Research Institute
Phase 1/2 Withdrawn
NCT02973191 2017-04-10
ORBIT
Celgene
Phase 1/2 Withdrawn
NCT00226993 2016-12-01
Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.
Stanford University
Phase 1/2 Withdrawn
NCT02141100 2016-10-07
Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma
Rigshospitalet, Denmark
Phase 1/2 Withdrawn
NCT02281279 2016-08-11
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Withdrawn
NCT02701673 2016-05-04
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT01528865 2016-03-11
Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma
University of Michigan Rogel Cancer Center
Phase 1/2 Withdrawn
NCT01180569 2015-09-25
Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Withdrawn
NCT00092274 2015-04-21
Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma
GlaxoSmithKline
Phase 1/2 Withdrawn